1. Бойцов С.А., Якушин С.С., Марцевич С.Ю. и др. Амбулаторно-поликлинический регистр кардиоваскулярных заболеваний РЕКВАЗА. Рацион. фармакотерапия в кардиологии. 2013; 7, 9 (1): 4–14.
2. Бубнова М.Г. Амлодипин в лечении сердечно-сосудистой патологии: доказанные антигипертензивный и антиатеросклеротический эффекты. Cons. Med. 2011; 13 (10): 95–9.
3. Гиляревский С.Р. Поиск универсальной комбинированной антигипертензивной терапии в условиях ограниченных данных о сравнительной эффективности антигипертензивных средств. Рацион. фармакотерапия в кардиологии. 2013; 9 (6): 664–77.
4. Кабалава Ж.Д., Котовская Ю.В. Европейские рекомендации по артериальной гипертонии 2013 года: неизменное, новое, нерешенное. Кардиология. 2013; 12: 83–95.
5. Козиолова Н.А., Шатунова И.М. Стратегия, тактические подходы и выбор комбинированной терапии в лечении больных артериальной гипертензией. Кардиология. 2013; 10: 71–81.
6. Оганов Р.Г., Масленникова Г.Я. Демографические тенденции в Российской Федерации: вклад болезней системы кровообращения. Кардиоваск. терапия и профилактика. 2012; 11 (1): 5–10.
7. Чазова И.Е., Ощепкова Е.В. Итоги реализации Федеральной целевой программы по профилактике и лечению артериальной гипертензии в России в 2002–2012 гг. Вестн. РАМН. 2013; 2: 4–11.
8. Bekki H, Yamamoto P, Sone M et al. Efficacy of combination therapy with telmisartan plus amlodipin in patient with poorly controlled hypertension. Oxid Med Cell Longer 2010; 3 (5): 342–6.
9. Bekki H, Yamamoto P, Sone M et al. Beneficial cardiomethabolic action of telmisartan plus amlodipin therapy in elderly patient with poorly controlled hypertension. Clin Cardiol 2011; 34 (4): 261–5.
10. Billecke SS, Marcovitz PA. Long-term safety and efficacy of telmisartan/amlodipine single pill combination in the treatment of hypertensior. Vasc Health Risk Manag 2013; 9: 95–104.
11. ESH/ESC Tasc force for the managerment of arterial hypertension. 2013 practice guidelines for the management of arterial hypertension of the Europian Society of Hypertension (ESH) and the Europian Society of Cardiology (ESC). J Hypertens 2013; 311925–38.
12. Fogari R, Derosa G, Zoppi A et al. Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patient with microalbuminuria. Am J Hypertens 2007; 20 (4): 417–22.
13. Go AS, Mozaffarian D, Roger VL et al. Heart disease and Stroke statistics-2012 update: a report from the American Heart Association. Circulation 2013; 127: e6–e245.
14. Guthrie RM, Dahlof B, Jamerson KA et al. Efficacy and tolerability of telmisartan plus amlodipine in added-risk hypertensive patient. Curr Med Res Opin 2011; 27 (10): 1995–2008.
15. James PA, Oparil S, Carter BL et al. Evidence-Based Guideline for the management of high blood pressure in adults. Report from the panel members appointed to the eighth joint national committee. JAMA 2014; doi:10.1001/jama.2013.2844
16. Ma L, Wang W, Zhao Y et al. Combination of amlodipine plus angiotensin receptor blocker of diuretics in high-risk hypertensive patient: 
a 96-week efficacy and safety study. Am J Cardiovasс Drugs 2012; 
12 (2): 137–42.
17. Mallat SG. What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment? Cardiovasс Diabetology 2012; 11: 32.
18. Meredith PA, Eliott HL. Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet 1992; 22 (1): 22–31.
19. Messerli FH. Evolution of calcium antagonists: past, present and future. Clin Cardiol 2003; 26 (Suppl. 2): 1112–6.
20. Miura S, Karnia SS, Saku K. Review: angiotensin II type I receptor blockers: class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst 2011; 12 (1): 1–7.
21. Mori H, Okada Y, Arao T et al. Telmisartan at 80 mg/day increases high-molecular-weight adiponectin levels and improves insulinresistance in diabetic patients. Adv Ther 2012; 29 (7): 635–44.
22. Neldam S, Edwards C, Lang M, Jones R. Long-term tolerability and efficacy of single-pill combinations of telmisartan 40–80 mg plus amlodipine 5 or 10 mg in patients whose blood pressure was not initially controlled by amlodipine 5–10 mg: Open-label long-term follow-ups of the TEAMSTA-5 and TEAMSTA-10 studies. Curr Ther Res Clin Exp 2012: 73 (1–2): 65–84.
23. Pitt B, Buington RP, Fuberg CL et al. Effect of amlodipine on the progression of atherosclerosis and the occurence of clinical events. PREVENT Investigators. Circulation 2000; 102: 1503–10.
24. Ripley TR, Harrison D. The power to TRANSCEND. Lancet 2008; 
DOI: 10.1016/SO140-6736(08)61243-X. Available at: 
www.thelancet.com.
25. Segura J, Ruilope LM. A review of the benefits of early treatment initiation with single-pill combinations of telmisartan with amlodipine or hydroclorothiazide. Vasc Health Risk Manag 2013: 9: 521–8.
26. Stanger J, Su C, Roth W. Pharmacokineties of orally and intervenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patient. J Int Med Res 2000; 28 (4): 149–67.
27. Tomiyama H, Yamatada J, Koji Y et al. Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dymetilarginine levels. Am J Hypertens 2007; 20: 1305–11.
28. Verdecchia P,  Angeli F, Mazzotta G et al. The renin angiotensin system in the development of cardiovascular diseases: role of aliskiren in risk reduction. Vasс Health Risk Manag 2008; 4 (5): 971–81.
29. Zbang X, Kichuk MR, Mital S et al. Amlodipine promotes kininmediated nitric oxide production in coronary vacrovessels of falling human hearts. Am J Cardiol 1999; 84: 271–331.
30. Совершенствование системы оказания медицинской помощи больным сердечно-сосудистыми заболеваниями в Российской Федерации. 2014; old.rosminzdrav.ru/heaith/cardiovascular/97/YakovlevaTV-2.ppt
31. Мунгер М.А. Терапия блокаторами рецепторов ангиотензина и кардиоваскулярная протекция. Современная доказательная база и перспективы развития. Кардиоваск. терапия и профилактика. 2011; 10 (7): 93–104.
32. Benson et al. Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARγ–Modulating Activity. Hypertension 2004; 43: 993–1002.
33. Thomas W. Littlejohn et al Original Research: Telmisartan Plus Amlodipine in Patients with Moderate or Severe Hypertension: Results from a Subgroup Analysis of a Randomized, Placebo-Controlled, Parallel-Group, 4 x 4 Factorial Study. Postgraduate Medicine. 2009; 121 (2): 5–14.
34. White WB, Littlejohn TW, Majul CR et al. Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1–2 hypertension. Blood Press Monit 2010 Aug;15(4): 205–12.
35. Neldam S., Margreet L., Russell J. Telmisartan and Amlodipine Single-Pill Combinations vs Amlodipine Monotherapy for Superior Blood Pressure Lowering and Improved Tolerability in Patients With Uncontrolled Hypertension: Results of the TEAMSTA-5 Study.  J Clin Hypertens (Greenwich) 2011; 13: 459–66.
RU/TWY-141055

О.Л.Барбараш1,2, Т.Н.Зверева1,2

1. ФГБУ Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний СО РАМН, Кемерово;
2. ГБОУ ВПО Кемеровская государственная медицинская академия Минздрава России